Nag S, Bilous R, Kelly W, Jones S, Roper N, Connolly V
James Cook University Hospital, Middlesbrough, UK.
Diabet Med. 2007 Jan;24(1):10-7. doi: 10.1111/j.1464-5491.2007.02023.x.
To investigate the association between estimated glomerular filtration rate (eGFR) and total and cardiovascular mortality in a population-based cohort of diabetic subjects.
A longitudinal study using a population-based district diabetes register comprising 3288 subjects in South Tees, UK. The eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) study equation. Patients were stratified by baseline eGFR into five stages as per the National Kidney Foundation guidelines: Stage 1, eGFR > 90; Stage 2, eGFR 60-89; Stage 3, eGFR 30-59; Stage 4, eGFR 15-29; and Stage 5, eGFR < 15 ml/min per 1.73 m(2). Main outcome was all-cause and cardiovascular mortality between 1 January 1994 and 31 July 2004.
At baseline, mean age (58.4 years) differed between groups. Persons with lower eGFR were older (P < 0.001). Thirty-six percent (n = 1193, males 56%) had died by 10 years (cardiovascular cause in 60%). Median follow-up was 10.5 years amounting to 28 342 person years. Stages 4 and 5 (eGFR <or= 29 ml/min per 1.73 m(2)) were amalgamated for mortality analysis. Total and cardiovascular mortality increased with reduced eGFR. Adjusted hazard ratios (HR) [95% confidence interval (CI)] for all-cause mortality comparing groups 2 and 3, and 4 and 5 combined with group 1 were 1.28 (1.02, 1.60), 2.58 (2.05, 3.25) and 6.42 (4.25, 9.71), respectively. Adjusted HRs (95% CI) for mortality due to circulatory disease comparing groups 2 and 3, and 4 and 5 combined with group 1 were 1.50 (1.10, 2.06), 3.32 (2.41, 4.58) and 7.99 (4.69, 13.62), respectively.
In diabetic subjects, mortality increases significantly with reduced GFR. Low eGFR identifies patients at high risk of cardiovascular mortality who should be targeted for aggressive risk factor modification.
在一个基于人群的糖尿病患者队列中,研究估算肾小球滤过率(eGFR)与全因死亡率和心血管死亡率之间的关联。
采用一项纵向研究,使用英国南蒂斯地区基于人群的糖尿病登记册,其中包括3288名受试者。使用肾脏病膳食改良(MDRD)研究方程计算eGFR。根据美国国立肾脏基金会指南,将患者按基线eGFR分为五个阶段:1期,eGFR>90;2期,eGFR 60 - 89;3期,eGFR 30 - 59;4期,eGFR 15 - 29;5期,eGFR<15 ml/min per 1.73 m²。主要结局是1994年1月1日至2004年7月31日期间的全因死亡率和心血管死亡率。
在基线时,各分组的平均年龄(58.4岁)有所不同。eGFR较低的人群年龄更大(P<0.001)。到10年时,36%(n = 1193,男性占56%)的患者已死亡(60%死于心血管疾病)。中位随访时间为10.5年,总计28342人年。为进行死亡率分析,将4期和5期(eGFR≤29 ml/min per 1.73 m²)合并。全因死亡率和心血管死亡率随eGFR降低而增加。比较第2组和第3组以及第4组和第5组合并组与第1组,全因死亡率的调整后风险比(HR)[95%置信区间(CI)]分别为1.28(1.02,1.60)、2.58(2.05,3.25)和6.42(4.25,9.71)。比较第2组和第3组以及第4组和第5组合并组与第1组,循环系统疾病导致的死亡率的调整后HR(95%CI)分别为1.50(1.10,2.06)、3.32(2.41,4.58)和7.99(4.69,13.62)。
在糖尿病患者中,死亡率随GFR降低而显著增加。低eGFR可识别出心血管死亡率高风险的患者,应对这些患者进行积极的危险因素干预。